QHSLab (USAQ) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 13, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-19041
Entity Registrant Name	QHSLab, Inc.
Entity Central Index Key	0000856984
Entity Tax Identification Number	30-1104301
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	901 Northpoint Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, Address Line Three	West Palm
Entity Address, City or Town	Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33407
City Area Code	(929)
Local Phone Number	379-6503
Title of 12(b) Security	Common Stock, $0.0001 Par Value
Trading Symbol	USAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,815,508

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 155,557	$ 286,855
Accounts receivable	96,093	70,474
Inventory	73,153	65,740
Prepaid expenses and other current assets	71,888	22,713
Total current assets	396,691	445,782
Non-current assets:
Capitalized software development costs	223,390	186,271
Intangible assets, net	1,558,416	1,576,444
Total assets	2,178,497	2,208,497
Current Liabilities:
Accounts payable	33,045	20,370
Other current liabilities	46,328	58,615
Loans payable, current portion	342,239	253,865
Convertible notes payable, current portion	613,954	542,104
Total current liabilities	1,035,566	874,954
Non-current liabilities:
Accrued interest expenses	8,986	6,521
Loans payable, non-current portion	357,834	402,956
Convertible notes payable, non-current portion	100,000	100,000
Total non-current liabilities	466,820	509,477
Total liabilities	1,502,386	1,384,431
Stockholders’ Equity:
Common stock, 900,000,000 shares authorized, $0.0001 par value; 8,815,508 and 8,756,093 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	882	876
Unearned stock compensation	(3,484)	(6,968)
Additional paid-in capital	3,387,540	3,348,681
Accumulated deficit	(2,709,199)	(2,518,895)
Total stockholders’ equity	676,111	824,066
Total liabilities and stockholders’ equity	2,178,497	2,208,497
Series A Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	108	108
Series A-2 Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	$ 264	$ 264

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Common stock, shares authorized	900,000,000	900,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	8,815,508	8,756,093
Common stock, shares outstanding	8,815,508	8,756,093
Series A Preferred Stock [Member]
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	1,080,092	1,080,092
Preferred stock, shares outstanding	1,080,092	1,080,092
Series A-2 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	2,644,424	2,644,424
Preferred stock, shares outstanding	2,644,424	2,644,424

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue	$ 355,330	$ 304,336
Cost of revenue	166,642	170,757
Gross profit	188,688	133,579
Operating Expenses:
Sales and marketing	113,294	111,688
General and administrative	89,514	70,127
Research and development	28,979	28,021
Amortization	18,028
Total Operating Expenses	249,815	209,836
Net operating loss	(61,127)	(76,257)
Interest expense	127,157	10,429
Loss on extinguishment of debt	2,020
Net loss	$ (190,304)	$ (86,686)
Basic and diluted net loss per share	$ (0.02)	$ (0.01)
Weighted average shares outstanding (basic and diluted)	8,779,859	6,833,261

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series A-2 Preferred Stock [Member]	Common Stock [Member]	Unearned Stock Compensation [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 108		$ 656	$ (124,479)	$ 1,264,108	$ (1,748,719)	$ (608,326)
Beginning balance, shares at Dec. 31, 2020	1,080,092		6,562,735
Shares issued for services			$ 15	(89,419)	89,985		581
Conversion of notes payable			$ 50		194,161		194,211
Conversion of notes payable, shares			496,718
Stock-based compensation expense					8,920		8,920
Net loss						(86,686)	(86,686)
Shares issued for services, shares			150,000
Cancellation of shares			$ (10)		10
Cancellation of shares, shares			(100,000)
Amortization of unearned compensation				67,812			67,812
Ending balance, value at Mar. 31, 2021	$ 108		$ 711	(146,086)	1,557,184	(1,835,405)	(423,488)
Ending balance, shares at Mar. 31, 2021	1,080,092		7,109,453
Beginning balance, value at Dec. 31, 2021	$ 108	$ 264	$ 876	(6,968)	3,348,681	(2,518,895)	824,066
Beginning balance, shares at Dec. 31, 2021	1,080,092	2,644,424	8,756,093
Shares issued for services				3,484			3,484
Conversion of notes payable			$ 6		27,919		27,925
Conversion of notes payable, shares			59,415
Warrants issued with conversion of notes payable					2,020		2,020
Stock-based compensation expense					8,920		8,920
Net loss						(190,304)	(190,304)
Ending balance, value at Mar. 31, 2022	$ 108	$ 264	$ 882	$ (3,484)	$ 3,387,540	$ (2,709,199)	$ 676,111
Ending balance, shares at Mar. 31, 2022	1,080,092	2,644,424	8,815,508

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (190,304)	$ (86,686)
Adjustments to reconcile net loss to net cash from operating activities:
Amortization	18,028
Amortization of debt and warrant issuance costs	96,850
Stock-based compensation	8,920	8,920
Shares issued for services	3,484	68,393
Loss on extinguishment of debt	2,020
Changes in operating assets and liabilities:
Increase in accounts receivable	(25,619)	(9,975)
(Increase)/decrease in inventory	(7,413)	38,561
Increase in prepaid expenses and other current assets	(49,175)	(1,088)
Increase/(decrease) in accounts payable	12,675	(67,556)
Decrease in other current liabilities	(14,257)	(433)
Increase in accrued interest	7,360	16,972
Cash flows from operating activities	(137,431)	(32,892)
Investing activities:
Capitalized software	(37,119)	(26,882)
Cash flows from investing activities	(37,119)	(26,882)
Financing activities:
Proceeds of loan borrowings	128,500
Repayments of loan borrowings	(85,248)
Cash flows from financing activities	43,252
Change in cash	(131,298)	(59,774)
Cash and cash equivalents – beginning of year	286,855	94,342
Cash and cash equivalents - end of period	155,557	34,568
Supplemental disclosures of cash flow activity:
Cash paid for interest	18,519	21
Cash paid for taxes
Supplemental noncash investing and financing activity:
Debt and accrued interest converted to shares of common stock	$ 27,925	$ 194,211

The Company

The Company	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1. The Company QHSLab, Inc. (f/k/a USA Equities Corp.) (the “Company”, or the “Registrant”) was incorporated in Delaware on September 1, 1983 . On April 19, 2022, the Company changed its name to QHSLab, Inc. The Company is a medical device technology and software as a service (“SaaS”) company focused on enabling primary care physicians (“PCP’s”) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2. Going Concern The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, has negative operational cash flows and began recognizing revenues in the fourth quarter of fiscal 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company’s business is dependent upon its ability to achieve profitability and positive cash flows and, pending such achievement, future issuances of equity or other financings to fund ongoing operations. However, access to such funding may not be available on commercially reasonable terms, if at all. These condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Note 3. Basis of Presentation The condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes included in our Annual Report on Form 10- K for the year ended December 31, 2021. The accounting policies are described in the “Notes to the Consolidated Financial Statements” in the 2021 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The results of operations for the three months ended March 31, 2022 and 2021 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. Reclassifications Certain reclassifications were made to the prior condensed consolidated financial statements to conform to the current period presentation. There was no change to the previously reported net loss. Risks Related to COVID-19 Pandemic The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and the Company does not yet know the full extent of potential impacts on its business, financing or global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources and operations. Accounting Policies Use of Estimates : The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates. Principles of Consolidation Cash and Cash Equivalents Accounts Receivable Inventories : Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. The Company uses actual costs to determine its cost basis for inventories. Inventories consist of only finished goods. Capitalized Software Development Costs : Software development costs for internal-use software are accounted for in accordance with Accounting Standards Codification (“ASC”) 350-40, Internal-Use Software The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 223,390 186,271 no no Intangible Assets: Business Combination, Related Issues, Initial Measurement Intangibles, General Intangibles Other Than Goodwill Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances may result in an impact to the value of the assets. Convertible Notes Payable: Derivatives and Hedging Debt with Conversion and Other Options Revenue Recognition Pursuant to ASC Topic 606, Revenue from Contracts with Customers, To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. The Company includes shipping and handling fees billed to customers in revenue. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract. Research and Development For the three months ended March 31, 2022 and 2021, there were $ 28,979 28,021 Stock-based Compensation Share Based Payment Earnings Per Common Share no Income Taxes Accounting for Income Taxes, The Company has net operating losses of $ 2,709,199 begin to expire in 2027 Recently Issued Accounting Standards In August 2020, the Financial Accounts Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Capitalized Software and Intang

Capitalized Software and Intangible Assets	3 Months Ended
	Mar. 31, 2022
Research and Development [Abstract]
Capitalized Software and Intangible Assets	Note 4. Capitalized Software and Intangible Assets Non-current assets consist of the following at March 31, 2022 and December 31, 2021: Schedule of Intangible Assets Estimated Useful Life March 31, December 31, Capitalized Software TBD $ 223,390 $ 186,271 Intangible Assets: U.S. Method Patent 13.4 $ 967,500 $ 967,500 Web Domain N/A 161,250 161,250 Trademark N/A 483,750 483,750 Total Intangible Assets $ 1,612,500 $ 1,612,500 Accumulated amortization (54,084 ) (36,056 ) Intangible assets, net $ 1,558,416 $ 1,576,444 Capitalized software represents the development costs for internal-use software. The software application is still in development with costs continuing to be capitalized and no amortization expense being recognized yet. Capitalization will cease and amortization will begin once development is substantially complete. The Capitalized software costs will be amortized over the estimated life of the software. There were no The intangible assets represent the value the Company paid to acquire the trademark “AllergiEnd”, the web domain “AllergiEnd.com” along with the U.S. Method Patent registration relating to the allergy testing kit and related materials the Company distributes to physician clients. The Company acquired the intangible assets from MedScience Research Group as of June 23, 2021 for total consideration of $ 1,612,500 Business Combination, Related Issues, Initial Measurement. Intangibles, General Intangibles Other Than Goodwill 18,028 no

Loans Payable

Loans Payable	3 Months Ended
	Mar. 31, 2022
Loans Payable
Loans Payable	Note 5. Loans Payable On June 23, 2021, the Company entered into a purchase agreement to acquire certain assets from MedScience Research Group, Inc (“MedScience”) (See Note 4 for additional information). As part of that purchase agreement, the Company issued a Promissory Note with a principal sum of $ 750,000 586,716 644,158 On March 2, 2022, the Company entered into a fixed-fee short-term loan with its merchant bank and received $ 128,500 in loan proceeds. The loan payable, which is split between current and long-term liabilities on the Company’s condensed consolidated balance sheets, is due in August 2023. The loan is repaid by the merchant bank withholding an agreed-upon percentage of payments they process on behalf of the Company with a minimum of $ 16,305 117,117 . The prior fixed-fee short-term loan with the same merchant bank had a balance of $ 16,793

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 6. Convertible Notes Payable Convertible notes payable at March 31, 2022 and December 31, 2021, consist of the following: Schedule of Convertible Notes Payable March 31, December 31, Note 1 – Accredited investors $ - $ 25,000 Note 2 – Shareholder 100,000 100,000 Note 3 – Mercer Note 756,000 756,000 Total 856,000 881,000 Debt discount and issuance costs (142,046 ) (238,896 ) Total convertible notes payable 713,954 642,104 Less: current portion 613,954 542,104 Non-current portion $ 100,000 $ 100,000 Note 1 – Effective December 23, 2020, the Company issued a Convertible Promissory Note in the principal amount of $ 25,000 to a shareholder (Note 1). This Note was issued under a subscription agreement dated September 25, 2020 . As of March 31, 2022 and December 31, 2021, this note had $ 0 and $ 2,555 , respectively, of accrued interest. On February 23, 2022 the shareholder the outstanding principal of $ 25,000 along with accrued interest into 59,415 shares of common stock at a price of $ 0.47 per share . Additionally, the shareholder received warrants exercisable for two years to purchase 14,854 common shares at $ 0.705 per share. Note 2 – Effective May 7, 2021, the Company issued a Convertible Promissory Note in the principal amount of $ 100,000 to a shareholder (Note 2). The Note bears interest at the rate of 10 % per annum and matures on September 30, 2022 (the “Maturity Date”) at which date all outstanding principal and accrued and unpaid interest are due and payable. The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15-day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of September 30, 2022 at the option of the holder using the same conversion calculation . As of March 31, 2022 and December 31, 2021, this note had $ 8,986 and $ 6,521 , respectively, of accrued interest. Note 3 – Effective August 10, 2021, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which it issued to the investor an Original Issue Discount Secured Convertible Promissory Note (the “Note”) in the principal amount of $ 806,000 930,000 750,000 The principal amount of the Note and all interest accrued thereon is payable on August 10, 2022, and are secured by a lien on substantially all of the Company’s assets. The Note provides for interest at the rate of 5 0.65 0.65 0.65 On November 11, 2021, Mercer Street Global Opportunity Fund, LLC, converted $ 50,000 of the principal amount of the $ 806,000 Secured Convertible Promissory Note issued August 10, 2021, into 76,923 shares of the Company’s common stock at a price of $ 0.65 per share. The 930,000 Warrants are initially exercisable for a period of three years at a price of $ 1.25 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant. The shares issuable upon conversion of the Note and exercise of the Warrants are to be registered under the Securities Act of 1933, as amended, for resale by the investor as provided in the Registration Rights Agreement. The Warrants may be exercised by means of a “cashless exercise” if at any time the shares issuable upon exercise of the Warrant are not covered by an effective registration statement. The Company accounts for the allocation of its issuance costs to its Warrants in accordance with ASC 470-20, Debt with Conversion and Other Options The Company estimated the fair value of the Warrants utilizing the Black-Scholes pricing model, which is dependent upon several assumptions such as the expected term of the Warrants, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected term and expected dividend yield rate over the expected term. The Company believes this valuation methodology is appropriate for estimating the fair value of warrants. The value allocated to the relative fair value of the Warrants was recorded as debt issuance costs and additional paid in capital. The principal, net of the original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, which are being recognized over the life of the Note, along with associated interest, is recorded with current liabilities on the Company’s condensed consolidated balance sheets. As of March 31, 2022, this Note had $ 24,767 of accrued interest, total unamortized debt issuance costs of $ 121,794 , including the Warrant value, and the remaining discount of $ 20,252 . As of December 31, 2021, this note had $ 15,446 of accrued interest, total unamortized debt issuance costs of $ 204,835 , including the Warrant value, and the remaining discount of $ 34,060 .

Preferred Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Preferred Stock	Note 7. Preferred Stock Series A Preferred Stock The shares of Series A Preferred Stock have a stated value of $ 0.25 0.05 The Series A Preferred Stock does not accrue dividends and ranks prior to the common stock upon a liquidation of the Company. The Series A Preferred Stock votes on all matters brought before the shareholders together with the Common stock as a single class and each share of Series A Preferred Stock has a number of votes, initially 5, equal to the number of shares of preferred stock into which it is convertible as of the record date for any vote. Series A-2 Preferred Stock On December 30, 2021, the Company issued 2,644,424 of the Company’s Series A-2 Convertible Preferred Shares to its principal shareholder in satisfaction of multiple outstanding convertible promissory notes with initial principal amounts totaling $ 286,078 together with all interest accrued thereon. The rights of holders of the Company’s common stock with respect to the payment of dividends and upon liquidation are junior in right of payment to holders of the Series A-2 Convertible Preferred Shares. The rights of the holders of the Company’s Series A-2 Preferred Shares are pari passu to the rights of the holders of the Company’s Series A Preferred Shares currently outstanding. Holders of the Series A-2 Convertible Preferred Stock will vote on an as converted basis with the holders of the Company’s common stock and Series A Preferred Shares as to all matters to be voted on by the holders of the common stock. Each Series A-2 Preferred Share shall be entitled to a number of votes equal to five times the number of shares of common stock into which it is then convertible on the applicable record date.

Loss Per Common Share

Loss Per Common Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Loss Per Common Share	Note 8. Loss Per Common Share The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include shares issuable upon exercise or conversion of outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the quarters ended March 31, 2022 and 2021 as the result would be anti-dilutive. Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share 2022 2021 Three Months Ended March 31, 2022 2021 Stock options 1,100,000 650,000 Stock warrants 1,026,647 - Total shares excluded from calculation 2,126,647 650,000

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Note 9. Stock-based Compensation During the three-month periods ended March 31, 2022 and 2021, there was $ 8,920 in stock-based compensation associated with stock options included in Research and development expense. Additionally, during the same periods there was expense associated with shares issued for services. The following table shows how the expenses associated with shares issued for services were classified in the condensed consolidated statements of operations during the respective periods. Schedule of Stock-based Compensation Expenses 2022 2021 Three Months Ended March 31, 2022 2021 Research and development $ - $ 21,625 Sales and marketing - 29,187 General and administrative 3,484 17,581 Total expense – shares issued for services $ 3,484 $ 68,393 During the three months ended March 31, 2021 there were 450,000 0.65 three years five years During the three months ended March 31, 2022 there were no options granted. As of March 31, 2022, there was $ 27,164 1,100,000 11 0.12 The fair value of all options granted is determined using the Black-Scholes option-pricing model. The following weighted-average assumptions were used: Schedule of Fair Value of Option Grant of Weighted-average Assumptions Three Months Ended Three Months Ended Risk-free interest rate N/A 0.21 % Expected life of the options N/A 3.5 Expected volatility of the underlying stock N/A 76.3 % Expected dividend rate N/A 0 % The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected term of the options. The expected life of the options is based on the option term. Due to the Company’s limited historical data, the expected volatility is calculated based upon the historical volatility of comparable companies whose share prices are publicly available for a sufficient period of time. The dividend rate is based on the Company never paying or having the intent to pay any cash dividends. Options outstanding at March 31, 2022 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date March 12, 2020 500,000 333,333 $ 0.40 March 12, 2025 June 27, 2020 150,000 100,000 $ 0.40 June 27, 2025 January 1, 2021 450,000 150,000 $ 0.65 December 31, 2025 Total 1,100,000 583,333 Warrants outstanding at March 31, 2022 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date March 16, 2021 15,900 15,900 $ 0.75 March 15, 2023 May 7, 2021 53,704 53,704 $ 0.74 May 6, 2023 June 17, 2021 12,189 12,189 $ 0.83 June 16, 2023 August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 February 23, 2022 14,854 14,854 $ 0.705 February 22, 2024 Total 1,026,647 1,026,647

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 10. Related Party Transactions Convertible notes payable, related party:

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 11. Income Taxes For the three month period ended March 31, 2022 and the year ended December 31, 2021, the Company did not record a tax provision as the Company did not earn any taxable income in either period and maintains a full valuation allowance against its net deferred tax assets.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies On February 9, 2021, the Company entered into a Receivables Purchase and Security Agreement (“Factoring Agreement”) with a Factoring Company. The Factoring Agreement has an initial term of one year Under the terms of the agreement, designated receivables are sold for periodic advances of up to $ 150,000 10 1.8 As of March 31, 2022, the balance of outstanding invoices that the Factoring Company may assign back to the Company if not collected within 90 days is included in the Company’s Accounts Receivable balance with the amounts received, net of reserves held, included with other current liabilities on the condensed consolidated balance sheets. The net amount included in other current liabilities is $ 10,334 25,420 There are no pending or threatened legal proceedings as of March 31, 2022. The Company has no non-cancellable operating leases.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates : The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
Principles of Consolidation	Principles of Consolidation
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable
Inventories	Inventories : Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. The Company uses actual costs to determine its cost basis for inventories. Inventories consist of only finished goods.
Capitalized Software Development Costs	Capitalized Software Development Costs : Software development costs for internal-use software are accounted for in accordance with Accounting Standards Codification (“ASC”) 350-40, Internal-Use Software The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 223,390 186,271 no no Intangible Assets: Business Combination, Related Issues, Initial Measurement Intangibles, General Intangibles Other Than Goodwill Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances may result in an impact to the value of the assets. Convertible Notes Payable: Derivatives and Hedging Debt with Conversion and Other Options
Revenue Recognition	Revenue Recognition Pursuant to ASC Topic 606, Revenue from Contracts with Customers, To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. The Company includes shipping and handling fees billed to customers in revenue. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract.
Research and Development	Research and Development For the three months ended March 31, 2022 and 2021, there were $ 28,979 28,021
Stock-based Compensation	Stock-based Compensation Share Based Payment
Earnings Per Common Share	Earnings Per Common Share no
Income Taxes	Income Taxes Accounting for Income Taxes, The Company has net operating losses of $ 2,709,199 begin to expire in 2027
Recently Issued Accounting Standards	Recently Issued Accounting Standards In August 2020, the Financial Accounts Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Indefinite-Lived Intangible Assets	Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life

Capitalized Software and Inta_2

Capitalized Software and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Research and Development [Abstract]
Schedule of Intangible Assets	Non-current assets consist of the following at March 31, 2022 and December 31, 2021: Schedule of Intangible Assets Estimated Useful Life March 31, December 31, Capitalized Software TBD $ 223,390 $ 186,271 Intangible Assets: U.S. Method Patent 13.4 $ 967,500 $ 967,500 Web Domain N/A 161,250 161,250 Trademark N/A 483,750 483,750 Total Intangible Assets $ 1,612,500 $ 1,612,500 Accumulated amortization (54,084 ) (36,056 ) Intangible assets, net $ 1,558,416 $ 1,576,444

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable at March 31, 2022 and December 31, 2021, consist of the following: Schedule of Convertible Notes Payable March 31, December 31, Note 1 – Accredited investors $ - $ 25,000 Note 2 – Shareholder 100,000 100,000 Note 3 – Mercer Note 756,000 756,000 Total 856,000 881,000 Debt discount and issuance costs (142,046 ) (238,896 ) Total convertible notes payable 713,954 642,104 Less: current portion 613,954 542,104 Non-current portion $ 100,000 $ 100,000

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share	Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share 2022 2021 Three Months Ended March 31, 2022 2021 Stock options 1,100,000 650,000 Stock warrants 1,026,647 - Total shares excluded from calculation 2,126,647 650,000

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expenses	Schedule of Stock-based Compensation Expenses 2022 2021 Three Months Ended March 31, 2022 2021 Research and development $ - $ 21,625 Sales and marketing - 29,187 General and administrative 3,484 17,581 Total expense – shares issued for services $ 3,484 $ 68,393
Schedule of Fair Value of Option Grant of Weighted-average Assumptions	The fair value of all options granted is determined using the Black-Scholes option-pricing model. The following weighted-average assumptions were used: Schedule of Fair Value of Option Grant of Weighted-average Assumptions Three Months Ended Three Months Ended Risk-free interest rate N/A 0.21 % Expected life of the options N/A 3.5 Expected volatility of the underlying stock N/A 76.3 % Expected dividend rate N/A 0 %
Schedule of Options Outstanding and Exercisable	Options outstanding at March 31, 2022 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date March 12, 2020 500,000 333,333 $ 0.40 March 12, 2025 June 27, 2020 150,000 100,000 $ 0.40 June 27, 2025 January 1, 2021 450,000 150,000 $ 0.65 December 31, 2025 Total 1,100,000 583,333
Schedule of Warrants Outstanding and Exercisable	Warrants outstanding at March 31, 2022 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Number Exercise Price Expiration Date March 16, 2021 15,900 15,900 $ 0.75 March 15, 2023 May 7, 2021 53,704 53,704 $ 0.74 May 6, 2023 June 17, 2021 12,189 12,189 $ 0.83 June 16, 2023 August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 February 23, 2022 14,854 14,854 $ 0.705 February 22, 2024 Total 1,026,647 1,026,647

Schedule of Indefinite-Lived In

Schedule of Indefinite-Lived Intangible Assets (Details)	3 Months Ended
	Mar. 31, 2022
Web Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired intangible asset	Indefinite life
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired intangible asset	Indefinite life
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	13 years 4 months 24 days

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Capitalized software development costs for software sold to customers	$ 223,390		$ 186,271
Capitalized computer software, amortization	0		0
Capitalized computer software, impairments	0		$ 0
Research and development expense	$ 28,979	$ 28,021
Common stock equivalent shares of weighted average shares outstanding dilutive	2,126,647	650,000
Operating loss carryforwards	$ 2,709,199
Net operating losses carryforwards, expire date	begin to expire in 2027
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalent shares of weighted average shares outstanding dilutive	0		0

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 1,612,500	$ 1,612,500
Intangible Assets:
Accumulated amortization	(54,084)	(36,056)
Intangible assets, net	1,558,416	1,576,444
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	223,390	186,271
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 967,500	967,500
Intangible Assets:
Finite-lived intangible assets, amortization method	13 years 4 months 24 days
Web Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 161,250	161,250
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Total Intangible Assets	$ 483,750	$ 483,750

Capitalized Software and Inta_3

Capitalized Software and Intangible Assets (Details Narrative) - USD ($)	Jun. 23, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Research and Development [Abstract]
Capitalized computer software, impairments		$ 0		$ 0
Acquired intangible assets	$ 1,612,500
Amortization expense		$ 18,028

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - USD ($)	Mar. 02, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 23, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt default longterm debt amount		$ 586,716	$ 644,158
Proceeds from Issuance of Debt	$ 128,500
Payments for loan	$ 16,305
Loan payable		$ 117,117
Merchant Bank [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Loan payable			$ 16,793
Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument face amount				$ 750,000

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Total	$ 856,000	$ 881,000
Debt discount and issuance costs	(142,046)	(238,896)
Total convertible notes payable	713,954	642,104
Less: current portion	613,954	542,104
Non-current portion	100,000	100,000
Convertible Notes Payable One [Member] | Accredited Investor [Member]
Short-Term Debt [Line Items]
Total		25,000
Convertible Notes Payable Two [Member] | Shareholder [Member]
Short-Term Debt [Line Items]
Total	100,000	100,000
Convertible Notes Payable Three [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Total	$ 756,000	$ 756,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	Nov. 11, 2021	Aug. 10, 2021	May 07, 2021	Dec. 23, 2020	Mar. 31, 2022	Mar. 31, 2021	Aug. 10, 2022	Feb. 23, 2022	Dec. 31, 2021	Nov. 15, 2021	Sep. 21, 2021
Short-Term Debt [Line Items]
Interest Payable, Current					$ 24,767				$ 15,446
Stock Issued During Period, Value, Conversion of Convertible Securities					27,925	$ 194,211
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net					121,794				204,835
Debt Instrument, Unamortized Discount					20,252				34,060
Convertible Promissory Note Ten [Member]
Short-Term Debt [Line Items]
Debt instrument convertible conversion price1										$ 0.65	$ 0.65
Convertible Promissory Note Ten [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Debt instrument convertible conversion price1							$ 0.65
Debt instrument interest rate stated percentage							5.00%
Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount	$ 806,000
Debt instrument convertible conversion price1	$ 0.65
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	930,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.25
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 50,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	76,923
Convertible Notes Payable One [Member] | Accredited Investor [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount				$ 25,000				$ 25,000
Debt Instrument, Maturity Date				Sep. 25, 2020
Interest Payable, Current					0			$ 59,415	2,555
Debt instrument convertible conversion price1								$ 0.47
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								14,854
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.705
Convertible Notes Payable Two [Member] | Shareholder [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount			$ 100,000
Debt Instrument, Maturity Date			Sep. 30, 2022
Interest Payable, Current					$ 8,986				$ 6,521
Debt instrument interest rate stated percentage			10.00%
Debt Instrument, Description			The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15-day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of September 30, 2022 at the option of the holder using the same conversion calculation
Convertible Notes Payable Three [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount		$ 806,000
Warrants to purchase common stock		930,000
Proceeds from Warrant Exercises		$ 750,000

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($)	Dec. 30, 2021	Sep. 01, 2019	Mar. 31, 2022	Dec. 31, 2021
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock stated value		$ 0.25	$ 0.0001	$ 0.0001
Debt instrument, conversion price		$ 0.05
Preferred stock voting rights description		The Series A Preferred Stock does not accrue dividends and ranks prior to the common stock upon a liquidation of the Company. The Series A Preferred Stock votes on all matters brought before the shareholders together with the Common stock as a single class and each share of Series A Preferred Stock has a number of votes, initially 5, equal to the number of shares of preferred stock into which it is convertible as of the record date for any vote.
Series A2 Convertible Preferred Shares [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, New Issues	$ 2,644,424
Debt Instrument, Face Amount	$ 286,078

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded From Calculation of Earning Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	2,126,647	650,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	1,100,000	650,000
Stock Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	1,026,647

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expenses (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total expense – shares issued for services	$ 3,484	$ 68,393
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total expense – shares issued for services		21,625
Selling and Marketing Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total expense – shares issued for services		29,187
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total expense – shares issued for services	$ 3,484	$ 17,581

Schedule of Fair Value of Optio

Schedule of Fair Value of Option Grant of Weighted-average Assumptions (Details)	3 Months Ended
	Mar. 31, 2021
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	0.21%
Expected life of the options	3 years 6 months
Expected volatility of the underlying stock	76.30%
Expected dividend rate	0.00%

Schedule of Options Outstanding

Schedule of Options Outstanding and Exercisable (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Option One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Mar. 12, 2020
Number Outstanding	500,000
Number Exercisable	333,333
Exercise Price | $ / shares	$ 0.40
Expiration Date	Mar. 12, 2025
Option Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jun. 27, 2020
Number Outstanding	150,000
Number Exercisable	100,000
Exercise Price | $ / shares	$ 0.40
Expiration Date	Jun. 27, 2025
Option Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jan. 1, 2021
Number Outstanding	450,000
Number Exercisable	150,000
Exercise Price | $ / shares	$ 0.65
Expiration Date	Dec. 31, 2025
Options Held [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding	1,100,000
Number Exercisable	583,333

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding and Exercisable (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Warrant One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Mar. 16, 2021
Number Outstanding	15,900
Number Exercisable	15,900
Exercise Price | $ / shares	$ 0.75
Expiration Date	Mar. 15, 2023
Warrant Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	May 7, 2021
Number Outstanding	53,704
Number Exercisable	53,704
Exercise Price | $ / shares	$ 0.74
Expiration Date	May 6, 2023
Warrant Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jun. 17, 2021
Number Outstanding	12,189
Number Exercisable	12,189
Exercise Price | $ / shares	$ 0.83
Expiration Date	Jun. 16, 2023
Warrant Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Aug. 10, 2021
Number Outstanding	930,000
Number Exercisable	930,000
Exercise Price | $ / shares	$ 1.25
Expiration Date	Aug. 9, 2024
Warrant Five [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Feb. 23, 2022
Number Outstanding	14,854
Number Exercisable	14,854
Exercise Price | $ / shares	$ 0.705
Expiration Date	Feb. 22, 2024
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding	1,026,647
Number Exercisable	1,026,647

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share-Based Payment Arrangement, Noncash Expense	$ 8,920	$ 8,920
Unrecognized compensation related to unvested options	$ 27,164
Unrecognized compensation related to unvested options, shares	1,100,000
Recognized weighted-average period	11 months
Weighted-average fair value for options granted		$ 0.12
Scientific Advisors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of options granted		450,000
Weighted-average exercise price		$ 0.65
Options vesting term		3 years
Options expiration period		5 years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Feb. 09, 2021	Mar. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other current liabilities		$ 46,328	$ 58,615
Factoring Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement term	1 year
Advances on sale on receivables	$ 150,000
Reserve of purchased receivables, percentage	10.00%
Factoring fees, percentage	1.80%
Other current liabilities		$ 10,334	$ 25,420